IGM Biosciences Inc. (IGMS) Records 0.64 million Shares Traded, Reaches $7.39 High


After finishing at $7.21 in the prior trading day, IGM Biosciences Inc. (NASDAQ: IGMS) closed at $7.36, up 2.08%. In other words, the price has increased by $+0.15 from its previous closing price. On the day, 636323 shares were traded. IGMS stock price reached its highest trading level at $7.39 during the session, while it also had its lowest trading level at $7.00.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free


Our goal is to gain a better understanding of IGMS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.10 and its Current Ratio is at 9.10. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 03 when Gauthier George sold 936 shares for $9.42 per share. The transaction valued at 8,818 led to the insider holds 40,017 shares of the business.

Topsoe Jakob Haldor bought 3,500 shares of IGMS for $32,375 on Jun 30. The Director now owns 81,644 shares after completing the transaction at $9.25 per share. On Jun 30, another insider, Topsoe Christina Teng, who serves as the Director of the company, bought 3,000 shares for $9.32 each. As a result, the insider paid 27,957 and bolstered with 9,800 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IGMS now has a Market Capitalization of 429.57M and an Enterprise Value of 84.12M. For the stock, the TTM Price-to-Sale (P/S) ratio is 247.51 while its Price-to-Book (P/B) ratio in mrq is 1.28. Its current Enterprise Value per Revenue stands at 52.87 whereas that against EBITDA is -0.36.

Stock Price History:

Over the past 52 weeks, IGMS has reached a high of $28.20, while it has fallen to a 52-week low of $6.45. The 50-Day Moving Average of the stock is 8.62, while the 200-Day Moving Average is calculated to be 14.36.

Shares Statistics:

The stock has traded on average 296.16K shares per day over the past 3-months and 280.64k shares per day over the last 10 days, according to various share statistics. A total of 45.12M shares are outstanding, with a floating share count of 21.42M. Insiders hold about 1.00% of the company’s shares, while institutions hold 61.60% stake in the company. Shares short for IGMS as of Aug 30, 2023 were 5.64M with a Short Ratio of 5.64M, compared to 4.88M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 9.67% and a Short% of Float of 37.23%.

Earnings Estimates

Its stock is currently analyzed by 10 different market analysts. On average, analysts expect EPS of -$1.24 for the current quarter, with a high estimate of -$1.05 and a low estimate of -$1.49, while EPS last year was -$1.32. The consensus estimate for the next quarter is -$1.28, with high estimates of -$1.08 and low estimates of -$1.54.

Analysts are recommending an EPS of between -$3.94 and -$5.77 for the fiscal current year, implying an average EPS of -$5.13. EPS for the following year is -$4.5, with 11 analysts recommending between -$2.92 and -$6.46.

Revenue Estimates

10 analysts predict $780k in revenue for the current quarter. It ranges from a high estimate of $1.01M to a low estimate of $450k. As of the current estimate, IGM Biosciences Inc.’s year-ago sales were $250k, an estimated increase of 212.00% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $870k, an increase of 133.90% less than the figure of $212.00% in the same quarter last year. There is a high estimate of $1.28M for the next quarter, whereas the lowest estimate is $450k.

A total of 11 analysts have provided revenue estimates for IGMS’s current fiscal year. The highest revenue estimate was $3M, while the lowest revenue estimate was $1.87M, resulting in an average revenue estimate of $2.66M. In the same quarter a year ago, actual revenue was $1.07M, up 148.80% from the average estimate.


Please enter your comment!
Please enter your name here